Current stock page

Financial Data

GMAB Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

GMABGenmab A/S

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$51.37−$0.37 (−0.72%)

Latest quote

  • Momentum
    94
  • Value
    71
  • Quality
    72
  • Risk resilience
    58
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$1.19B$1.16B$899.32M$1.05B$1.02B$924.81M$105.23M$6.44B
Gross Profit$1.1B$1.07B$834.08M$974.05M$964M$867.82M$99.05M$6.1B
Operating Income$441M$407M$225.83M$242.27M$459M$359.92M$27.67M$2.16B
Net Income$342M$303M$53.2M$30.91M$401M$335.93M$28.7M$3.85B
EPS$0.56$0.49$0.09$0.05$0.65$0.54$0.05$5.99
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$520M$51M$3.01M$300.34M$536M$61.99M$287M$326.44M
Capital Expenditure-$11M-$3M-$5.02M-$12.99M-$2M-$10M-$30M-$26.99M
Free Cash Flow$509M$48M-$2.01M$287.35M$534M$51.99M$257M$299.45M
Net Cash Provided By Operating Activities$520M$51M$3.01M$300.34M$536M$61.99M$287M$326.44M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$12.94B$12.52B$12.38B$12.84B$7.02B$6.46B$6.03B$45.81B
Total Debt$5.2B$5.27B$5.35B$5.43B$142M$147.97M$138.04M$1.03B
Cash And Cash Equivalents$1.86B$1.5B$1.52B$1.71B$1.76B$1.3B$1.21B$9.86B
Total Liabilities$6.6B$6.56B$6.69B$7.01B$1.27B$1.16B$1.08B$9.11B
Total Stockholders Equity$6.33B$5.96B$5.68B$5.83B$5.75B$5.3B$4.95B$36.7B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio45.6623.3621.0525.334.1—9.59—
P/B ratio5.263.093.043.463.29—2.51—
P/S ratio7.33———————
Debt To Equity0.820.890.940.930.020.030.030.03
Free Cash Flow Yield2.53%4.71%5.04%5.60%6.04%—18.06%—
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio45.6623.3621.0525.334.1—9.59—
P/B ratio5.263.093.043.463.29—2.51—
P/S ratio7.33———————
Return On Equity11.51%13.23%14.45%13.65%80.17%103.30%108.04%15.00%
Debt To Equity0.820.890.940.930.020.030.030.03

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe42.8x
Pb4.92x
Revenue Growth Yoy16.14%
EPS Growth Yoy-13.85%
Gross Margin92.60%
Operating Margin30.53%
ROE12.26%
ROIC10.27%
Debt To Equity0.82
FCF Yield2.70%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$51.37
Volume3.73M
RSI (14)59.07
MACD3.86
MACD signal4.42
MACD histogram-0.56
ADX (14)45.83
SMA (50)$41.15
SMA (200)$31.54
ATR (14)$2.32
Historical volatility (annualized)110.89%
Volume (20-day average)6.57M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score58/100
Beta0.93
Annual volatility45.85%
Max Drawdown-32.51%
Sharpe Ratio1.29
VaR (95%, 1-day)-3.16%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

GMAB Financial Data FAQ

What is Genmab A/S's revenue?

Genmab A/S's revenue is one of the core financial data points for GMAB. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Genmab A/S's revenue growing?

Revenue growth shows whether Genmab A/S is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is GMAB's EPS?

GMAB's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Genmab A/S's net income?

Genmab A/S's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Genmab A/S generate?

Free cash flow shows how much cash Genmab A/S generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Genmab A/S have?

Cash and debt help frame GMAB's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.